The Cooperative Agreement will build upon the extensive experience of an institution with well-established and globally recognized collaboration with inspectorates of National Regulatory Authorities (NRAs) around the globe in support of data-driven and science-based regulatory and public health strategies
and approaches that align with FDA domestic and global priorities to assure a pharmaceutical quality integration of assessment, inspection, policy, and research activities within a pharmaceutical context, including Good Manufacturing Practices (GMP).
The funding will catalyze and support the institution's activities that are focused on consensus around what optimal good manufacturing practices are and the competencies for Inspectors within the context of emerging and increasingly complex science, research and innovation in manufacturing of pharmaceutical products.
Based on such consensus, the institution and its network of NRA Inspectorates will work toward a systems-approach and sustainable alignment across and among NRA Inspectorates in GMP quality manufacturing.